Pharmalittle: We’re reading about MorphoSys drug risks, an AstraZeneca admission, and more
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.